Your Current Position: NEWS
-
【Company News】 Dean Zhong Zhengxiang and Doctor Bao Yi of Jiaxing 2nd Hospital came to Converd for academic exchange2018-02-22On February 3, 2018, Dr. Zhong Zhengxiang and Dr. Bao Zheng from Jiaxing 2nd Hospital came to our company for academic exchanges.
-
【Industry Trends】 Science Translational Medicine 10 (422): Oncolytic virus immunotherapy breakthrough again2018-02-01In the 10th issue of the 422th issue of Science Translational Medicine, the new results of oncolyticvirus-related immunotherapy were on the cover in the journal Science Translational Medicine 10(422).
-
Converd has completed and moved to its new R & D center in Hangzhou. The Center holds 1,000 m2 area of laboratory space for Molecular and Cellular biology
-
【Industry Trends】 Sep. 7, 2017 Cell: Oncolytic virus and c-Rel inhibitors make immunotherapy more effective2018-01-11Immunotherapy is a promising approach in the treatment of cancer; but for most patients, immunotherapy drugs so far have failed to live up to their promise and provide little or no benefit. Immunotherapy
-
【Company News】 Converd forms a partnership with China Resources (CR Pharmaceutical) in developing oncolytic virus therapy platform2017-12-15Converd has received investment in shares from CR Pharmaceutical(华润生命科学). This is a part of Converd’s B series financing, which also includes investments from Nanjing Jingyong Healthcare Capitals.
-
Professor Gao Daiqing came to our company for academic exchange on clinical research of immunotherapy.
-
【Company News】 Converd settled in Zhejiang Overseas High-Level Talents Innovation Park, Zhangjiang Hangzhou Future SCI-Tech City2015-10-13For further development, in February 2012, ConVerd registered HangzhouConVerd Co., Ltd. in Zhangjiang Hangzhou Future SCI-Tech City.
-
2015-07-23In July 2009, Suzhou Converd Co., Ltd. was founded in Kunshan Small Nucleic Acid Base, Suzhou, Jiangsu.
-
After one year of development, ConVerd won the investment of Hong Kong Morningside Venture Capital Group